Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Department of Psychiatry, University of Münster, Münster, Germany.
Schizophr Bull. 2022 Jan 21;48(1):241-250. doi: 10.1093/schbul/sbab110.
Schizophrenia is a complex and heterogeneous syndrome. Whether quantitative imaging biomarkers can identify discrete subgroups of patients as might be used to foster personalized medicine approaches for patient care remains unclear. Cross-sectional structural MR images of 163 never-treated first-episode schizophrenia patients (FES) and 133 chronically ill patients with midcourse schizophrenia from the Bipolar and Schizophrenia Network for Intermediate Phenotypes (B-SNIP) consortium and a total of 403 healthy controls were recruited. Morphometric measures (cortical thickness, surface area, and subcortical structures) were extracted for each subject and then the optimized subtyping results were obtained with nonsupervised cluster analysis. Three subgroups of patients defined by distinct patterns of regional cortical and subcortical morphometric features were identified in FES. A similar three subgroup pattern was identified in the independent dataset of patients from the multi-site B-SNIP consortium. Similarities of classification patterns across these two patient cohorts suggest that the 3-group typology is relatively stable over the course of illness. Cognitive functions were worse in subgroup 1 with midcourse schizophrenia than those in subgroup 3. These findings provide novel insight into distinct subgroups of patients with schizophrenia based on structural brain features. Findings of different cognitive functions among the subgroups support clinical differences in the MRI-defined illness subtypes. Regardless of clinical presentation and stage of illness, anatomic MR subgrouping biomarkers can separate neurobiologically distinct subgroups of schizophrenia patients, which represent an important and meaningful step forward in differentiating subtypes of patients for studies of illness neurobiology and potentially for clinical trials.
精神分裂症是一种复杂且异质的综合征。目前尚不清楚定量成像生物标志物是否可以识别离散的患者亚组,这些亚组可能用于促进针对患者护理的个性化医学方法。本研究招募了来自双相和精神分裂症网络中间表型(B-SNIP)联盟的 163 名未经治疗的首发精神分裂症患者(FES)和 133 名精神分裂症中期的慢性患者以及总共 403 名健康对照者的横断面结构磁共振成像。提取了每个受试者的形态测量指标(皮质厚度、表面积和皮质下结构),然后通过无监督聚类分析获得最优的亚分类结果。在 FES 中,根据区域皮质和皮质下形态特征的不同模式确定了 3 组患者亚组。在来自多地点 B-SNIP 联盟的患者的独立数据集也识别出了类似的 3 个亚组模式。这两个患者队列的分类模式的相似性表明,3 组分类在疾病过程中相对稳定。与亚组 3 相比,处于中期的精神分裂症亚组 1 的认知功能更差。这些发现基于结构脑特征为精神分裂症患者提供了新的深入了解不同亚组。亚组间不同认知功能的发现支持 MRI 定义的疾病亚型在临床上的差异。无论临床表现和疾病阶段如何,解剖学磁共振亚组化生物标志物都可以将精神分裂症患者的神经生物学上不同的亚组分开,这是区分患者亚型以进行疾病神经生物学研究和潜在临床试验的重要而有意义的一步。